Founder & Ceo
CurrentWith the main business scope of health care, Jiangsu Tingsn Technology Co., Ltd.has officially launched the research and development of an innovative interventional treatment product for cardiac arrhythmia -- the cardiac three-dimensional mapping system on January 23, 2019. Relying on the state key laboratory of Nanjing University, we have hired a number of professors and experts in various fields as our R & D consultants. Led by the postdoctoral from Purdue University, we have also built our own research and development team to achieve independent innovation in the heart internal catheter positioning and software algorithms.“Use Technology to Escort Your Health” is the dream pursued by all Tingsn people. Tingsn insists on independent innovation and keeps applying advanced technology to the products to shorten the competitive gap between international brands and made-in-china. Tingsn is constantly striving to build a Chinese nation brand by vigorously selling products to overseas markets.For more information, please open the website:www.tingsn.com.江苏霆升科技有限公司,主要经营健康医疗领域,于2019年1月23日正式启动针对心脏心律失常的创新介入治疗产品-心脏三维标测系统的研发工作,公司依托南京大学国家级重点实验室、美国普渡大学,聘请各领域多位教授担任研发顾问,由美国普渡大学博士后牵头组建研发团队,在心脏内部导管定位及软件算法上实现自主创新。 霆升科技正在研发的三维标测系统旨在降低手术器械成本/降低该类手术费用/降低病人家庭和医保负担,让全国7000多家县级医院真正都可以实现心脏介入手术治疗的当地化服务,提高手术的应用率,使得众多病患获益,努力实现打破国外公司目前对中国市场的技术和产品垄断,提升国产医疗器械技术含金量和技术自主程度,逐步实现介入治疗产品替代进口的愿望,并将产品大力销往海 外市场,力争实现打造“好产品made in china” 的民族品牌梦想。 官方网站:www.tingsn.com